China’s top securities regulator has signaled restarting a regulatory pathway to allow for unprofitable biotechnology and medical technology start-ups to go public on the Shanghai Stock Exchange (SSE).
The restoration of the special initial public offering (IPO) process, which was first introduced along with the launch of the...